Adagio Medical Holdings (NASDAQ:ADGM), a specialist in catheter ablation technologies for cardiac arrhythmias, reported a substantial narrowing of its net loss for the fiscal year ended Dec. 31, 2025, as the company realized the benefits of an aggressive cost-reduction strategy and a streamlined corporate profile.
The Laguna Hills, California-based company posted a net loss of $25.1 million for the full year 2025, a significant improvement from the $75 million loss recorded in 2024.
The fourth quarter was particularly lean, with a net loss of $3.3 million compared to $57.4 million in the same period a year earlier.
Management attributed the year-over-year improvement primarily to the absence of a $49.2 million non-cash impairment charge taken in 2024, alongside lower interest expenses and a favorable fair value revaluation of notes and warrants.
Operating costs fell sharply across all categories as the company focused on capital preservation.
Selling, general, and administrative expenses for the year dropped to $10.6 million from $20 million in 2024.
This nearly 50% reduction was driven by the elimination of one-time corporate expenses related to its 2024 SPAC transaction and a decrease in payroll costs following a reduction in headcount.
Research and development spending also moderated, falling to $10.6 million for the full year from $12.2 million in the prior year.
The company cited a decrease in quality assurance costs, a more selective approach to R&D projects, and lower personnel expenses as the primary drivers for the decline.
The company’s cost of revenue saw the most dramatic percentage shift, falling to $0.7 million for the full year from $3.3 million in 2024.
For the fourth quarter specifically, cost of revenue was just $58,000.
Adagio stated this was the result of a deliberate pause in commercial activity in Europe and an associated inventory buyback program, as the company pivoted its strategic focus.
Adagio ended the year with $17.1 million in cash and cash equivalents.